Skip to Content
Merck
All Photos(1)

Documents

V3388

Sigma-Aldrich

Vascular Endothelial Growth Factor (aa 207-318) human

≥97% (SDS-PAGE), recombinant, expressed in E. coli, lyophilized powder

Synonym(s):

VEGF112, Vasculotropin

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352202
NACRES:
NA.32

product name

Vascular Endothelial Growth Factor (aa 207-318) human, ≥97% (SDS-PAGE), recombinant, expressed in E. coli, lyophilized powder

biological source

human

Quality Level

recombinant

expressed in E. coli

Assay

≥97% (SDS-PAGE)

form

lyophilized powder

potency

0.75-3.75 ng/mL ED50

mol wt

predicted mol wt ~28 kDa

packaging

pkg of 5 μg

storage condition

avoid repeated freeze/thaw cycles

impurities

<1 EU/μg

UniProt accession no.

storage temp.

−20°C

Gene Information

human ... VEGFA(7422)

Application

Vascular Endothelial Growth Factor (aa 207-318) human also known as VEGF 121 was used for preparing a cellular matrix hybridized with hyaluronic acid (ACM-HA) VEGF constructs which is used in measuring the VEGF-enhanced tissue-engineered bladder graft neovascularization by using dynamic contrast-enhanced MRI. The product was used for creating VEGF-impregnated tissue-engineered construct which was inserted in the critical-sized calvarial defect in the membranous parietal bone of the rabbit for examining and characterizing the angiogenesis necessary for bone formation.

Biochem/physiol Actions

Vascular Endothelial Growth Factor (aa 207-318) human also referred to as VEGF 121 or Vasculotropin is a basic protein that induces endothelial cell growth, vasculogenesis and angiogenesis. VEGF also enhances the growth of endothelial cells isolated from cerebral cortex, fetal and adult aorta as well as human umbilical vein. Cells enhance VEGF 121 secretion from fibrin implants results in local and controlled blood vessel growth.
Potent angiogenesis inducer in vivo.

Other Notes

112 amino acid residue variant of human VEGF.

Physical form

Lyophilized from a 0.2 μm filtered solution in 30% acetronitrile and 0.1% TFA containing 0.25 mg bovine serum albumin.

Analysis Note

The biological activity is measured by its ability to stimulate 3H-thymidine incorporation in human umbilical vein endothelial cells.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Martin Ehrbar et al.
Circulation research, 94(8), 1124-1132 (2004-03-27)
Although vascular endothelial growth factor (VEGF) has been described as a potent angiogenic stimulus, its application in therapy remains difficult: blood vessels formed by exposure to VEGF tend to be malformed and leaky. In nature, the principal form of VEGF
Lisa Cartwright et al.
Journal of biomedical materials research. Part A, 77(2), 390-395 (2006-01-24)
Tissue engineered organs require an immediately perfused vascular tree. Currently, neovascularization assessment requires animal sacrifice and graft harvest. In this pilot study we assess whether neovascularization of an engineered urinary bladder construct is enhanced with vascular-derived endothelial growth factor (VEGF)
Sevan Evren et al.
Cells, tissues, organs, 192(4), 250-261 (2010-07-01)
Natural scaffolds have been shown to induce T helper 2 (TH2)-specific immune responses in host tissues; however, the precise mechanisms that underlie this immune response are unknown. Using a porcine animal model, we evaluated the role of Toll-like receptors (TLRs)
Marine Beaumont et al.
NMR in biomedicine, 23(1), 48-55 (2009-08-04)
Tissue engineering is a promising technique for bone repair and can overcome the major drawbacks of conventional autogenous bone grafting. In this in vivo longitudinal study, we proposed a new tissue-engineering paradigm: inserting a biological soft-tissue construct within the bone
Molecular and biological properties of the vascular endothelial growth factor family of proteins.
N Ferrara et al.
Endocrine reviews, 13(1), 18-32 (1992-02-01)

Articles

VEGF-A stimulates blood vessel growth via endothelial cell proliferation, migration, and survival during embryonic development.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service